Taiho Oncology To Present Futibatinib (TAS-120) Data In Advanced Intrahepatic Cholangiocarcinoma at ESMO Virtual Congress 2020
PRINCETON, N.J., Sept. 15, 2020 /PRNewswire/ -- Taiho Oncology, Inc. today announced data from three abstracts for futibatinib (TAS-120) in intrahepatic cholangiocarcinoma (iCCA) and in advanced solid tumors will be presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020. Key presentations include:
Additional information can be found here: https://virtualcongress2020.esmo.org/IndustryLandingPage/esmo/esmo2020/en-GB/profile/f1b7f52e-c2d0-47ef-88fd-282d5ffdde37
"We are pleased to present these new analyses of futibatinib in intrahepatic cholangiocarcinoma, as well as the results of our Phase 1 experience in Japanese patients," said Martin J. Birkhofer, MD, Senior Vice President and Chief Medical Officer, Taiho Oncology, Inc. "We look forward to further exploration of safety, efficacy and quality of life outcomes of this investigational compound to determine who may see the most benefit from it."
In May 2018, the U.S. Food and Drug Administration Office of Orphan Drug Development granted futibatinib orphan drug status for the treatment of cholangiocarcinoma.
The main treatment for CCA is surgery. Radiation therapy and chemotherapy may be used if the cancer cannot be entirely removed with surgery and in cases where the edges of the tissues removed at the operation show cancer cells (also called a positive margin). Both stage III and stage IV cancers cannot be completely removed surgically. Currently, standard treatment options are limited to radiation, palliative therapy, liver transplantation, surgery, chemotherapy and interventional radiology.2
About Futibatinib (TAS-120)
About Taiho Oncology, Inc. (U.S.)
For more information about Taiho Oncology, please visit:
For more information about Taiho Pharmaceutical Co., Ltd., please visit:
For more information about Otsuka Holdings Co., Ltd., please visit:
U.S. Media Contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/taiho-oncology-to-present-futibatinib-tas-120-data-in-advanced-intrahepatic-cholangiocarcinoma-at-esmo-virtual-congress-2020-301131024.html
SOURCE Taiho Oncology, Inc.